← Scroll for more →
Atara Biotherapeutics, Inc. (ATRA)
Biological Products, (No Diagnostic Substances)
Latest Price
$8.01
TTM P/E
--
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
0.08
P/B Ratio
105.26
Valuation metrics
adjust assumptions →EPS: $2.57
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$38.55
+345% upside
Institutional Ownership
46.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 1.55M | $17.0M | 16.44% | +1.45M | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 850.0K | $9.0M | 9.00% | +150.0K | 2026-06-30 |
| Point72 Asset Management, L.P. | 687.7K | $7.0M | 7.28% | +493.5K | 2026-06-30 |
| Redmile Group, LLC | 441.7K | $5.0M | 4.68% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 247.0K | $2.0M | 2.62% | +29.2K | 2026-06-30 |
| Mackenzie Financial Corp | 233.2K | $2.0M | 2.47% | -80.4K | 2026-06-30 |
| BlackRock, Inc. | 84.5K | -- | 0.89% | +5.4K | 2026-06-30 |
| Geode Capital Management, LLC | 75.1K | -- | 0.80% | +9.0K | 2026-06-30 |
| Staley Capital Advisers Inc | 50.0K | -- | 0.53% | -- | 2026-06-30 |
| Vanguard Fiduciary Trust Co | 43.0K | -- | 0.46% | +9.4K | 2026-06-30 |